XTL-002: XTL began a dose-escalating Phase Ib trial in 20 chronic HCV patients

XTL Biopharmaceuticals Ltd. (LSE:XTL), Rehovot,

Read the full 57 word article

How to gain access

Continue reading with a
two-week free trial.